Serum Tumor Markers for Malignancies (Commercial, BlueCare)

This policy (G2124) defines coverage for measurement of serum tumor markers for malignancies, specifying which serum/ circulating tumor biomarkers and clinical indications meet or do not meet coverage criteria and listing applicable CPT/HCPCS procedure codes. Coverage stance: mixed; status: CURRENT. The policy scope covers use of serum tumor markers for diagnosis, staging, monitoring, and surveillance of specified cancers and related conditions and requires documentation of the specific covered indication to support coverage.

Background: the management recommendations are built from the NCCN Biomarkers Compendium as the evidence basis, and the policy notes that many tests are laboratory-developed tests (LDTs) which are regulated under CLIA as high-complexity tests; FDA clearance or approval is not required for clinical use of LDTs.

Key stats: the policy lists 24+ covered analytes/markers, identifies 3 primary 'Not Covered' categories (other indications, other markers, proteomic pattern analysis), and includes 40+ CPT/HCPCS codes referenced for reporting tests.

Surveillance Intervals / Thresholds

AFP surveillance intervalEvery 3-6 months for 2 years, then every 6 months

CA 19-9 surveillance (ampullary/pancreatic)Every 3-6 months for 2 years, then every 6-12 months up to 5 years (as clinically indicated)

Germ cell tumor surveillanceNo more than every 2 months for first 2 years; every 4 months in years 3-5; then annually after year 5

Beta-hCG monitoring (gestational trophoblastic neoplasia)No more than weekly during treatment; no more than monthly for 12 months post-treatment

Serum free light chain surveillance (multiple myeloma)Up to once per month

General follow-up frequencyQuarterly measurement permitted for follow-up/monitoring/surveillance unless a different interval is specified

Medical-Necessity Criteria

Covered Indications (MEETS COVERAGE CRITERIA)

Measurement of the following serum tumor markers MEETS COVERAGE CRITERIA for the following indications:

ALL of the following

Alkaline phosphatase (ALP) — Indications: Bone neoplasms: workup; during treatment; surveillance; Systemic light chain amyloidosis: initial diagnostic workup.
Alpha fetoprotein (AFP) — Indications: Hepatocellular carcinoma: screening; workup for confirmed HCC; surveillance (every 3-6 months for 2 years, then every 6 months). Intrahepatic cholangiocarcinoma: workup for isolated intrahepatic mass.every 3-6 months for 2 years, then every 6 months
Beta-2 microglobulin (B2M) — Indications: B-cell lymphomas (Castleman disease; diffuse large B-cell; follicular [grade 1-2]; HIV-related; lymphoblastic; mantle cell): workup. Chronic lymphocytic leukemia/small lymphocytic lymphoma: workup for prognostic and/or therapy determination. Multiple myeloma: initial diagnostic workup; follow-up/surveillance for solitary plasmacytoma or solitary plasmacytoma with minimal marrow involvement. Systemic light chain amyloidosis: initial diagnostic workup. Waldenström macroglobulinemia / lymphoplasmacytic lymphoma: workup.
Beta human chorionic gonadotropin (beta-hCG) — Indications: Gestational trophoblastic neoplasia: initial workup; during and post treatment (no more than weekly); follow-up/surveillance (no more than monthly for 12 months). Occult primary: additional workup for localized adenocarcinoma or carcinoma NOS; individuals <65 years with testes presenting with retroperitoneal mass. Ovarian/fallopian tube/primary peritoneal cancer: initial workup; during primary chemotherapy; monitoring/follow-up for complete response (as clinically indicated). Ovarian cancers: borderlines, malignant germ cell tumors (surveillance no more than every 2 months first 2 years, every 4 months years 3-5, then annually), malignant sex cord stromal tumors (surveillance if clinically indicated; frequency stage-based). Testicular cancer (nonseminoma and pure seminoma): diagnostic workup; post-diagnostic workup; risk classification; surveillance (no more than every 2 months). Thymomas and thymic carcinomas: initial evaluation, if appropriate.no more than weekly during treatment; no more than monthly for 12 months post-treatment
BNP or NT-proBNP — Indications: Multiple myeloma: initial diagnostic workup. Systemic light chain amyloidosis: initial diagnostic workup.
Calcitonin (CALCA) — Indications: Adenocarcinoma and anaplastic/undifferentiated epithelial tumors: workup. Medullary carcinoma: additional workup; post-surgical evaluation; monitoring; surveillance (2-3 months postoperative, then every 6-12 months). Multiple endocrine neoplasia type 2: at diagnosis (clinical evaluation) for medullary thyroid cancer. Occult primary: workup.2-3 months postoperative, then every 6-12 months
CA 15-3 and 27.29 — Indications: Breast cancer (invasive): monitoring metastatic disease. Occult primary: suspected metastatic malignancy: initial workup assessing prognosis; monitoring/follow-up for response.
CA 19-9 — Indications: Ampullary adenocarcinoma: workup; surveillance (every 3-6 months for 2 years, then every 6-12 months up to 5 years as clinically indicated) for resected ampullary cancer stage I-III. Appendiceal adenocarcinoma: workup to establish baseline (trend abnormal measurements). Extrahepatic cholangiocarcinoma: baseline workup; monitoring. Gallbladder cancer: baseline workup; monitoring; surveillance post-resection as clinically indicated. Intrahepatic cholangiocarcinoma: baseline workup; monitoring. Occult primary: baseline workup; prognosis assessment; monitoring/follow-up for response. Ovarian/fallopian tube/primary peritoneal cancer: initial workup; during primary chemotherapy; monitoring/follow-up for complete response as clinically indicated. Pancreatic adenocarcinoma: baseline workup; monitoring; post-operative/post-adjuvant surveillance (every 3-6 months for 2 years, then every 6-12 months). Small bowel adenocarcinoma: baseline workup; post-treatment surveillance (every 3-6 months for 2 years, then every 6 months to 5 years); at metastasis or recurrence.every 3-6 months for 2 years, then every 6-12 months
CA-125 — Indications: Appendiceal adenocarcinoma: baseline workup. Endometrial carcinoma: additional workup; surveillance (if initially elevated). Lynch syndrome: surveillance. Occult primary: additional workup for adenocarcinoma or carcinoma NOS in those with a uterus and/or ovaries present. Ovarian/fallopian tube/primary peritoneal cancer: initial workup; during primary chemotherapy; monitoring/follow-up for complete response as clinically indicated. Ovarian cancer subtypes and surveillance frequency as specified (borderline epithelial tumors: monitoring every visit if initially elevated; malignant germ cell tumors, sex cord stromal tumors: surveillance schedule as specified). Peritoneal mesothelioma: initial evaluation. Uterine neoplasms: initial workup.
Carcinoembryonic antigen (CEA) — Indications: Appendiceal adenocarcinoma: baseline workup; monitoring; post-treatment surveillance. Breast cancer (invasive): monitoring metastatic disease. Colon cancer: baseline workup; monitoring; surveillance (every 3-6 months for 2 years, then every 6 months for total 5 years). Extrahepatic cholangiocarcinoma, gallbladder cancer, intrahepatic cholangiocarcinoma: baseline workup; monitoring; surveillance/post-resection monitoring as clinically indicated. Medullary carcinoma: diagnosis and additional workup; monitoring post-surgical surveillance (2-3 months postoperative, then every 6-12 months). Multiple endocrine neoplasia type 2: at diagnosis for medullary thyroid cancer. Ovarian/fallopian tube/primary peritoneal cancer: initial workup; during primary chemotherapy; monitoring/follow-up for complete response as clinically indicated. Rectal cancer: baseline workup; monitoring; surveillance (every 3-6 months for 2 years, then every 6 months to 5 years). Small bowel adenocarcinoma: baseline workup; post-treatment surveillance schedule as specified.every 3-6 months for 2 years, then every 6 months
Inhibin (INHA) — Indications: Adrenocortical carcinoma: workup. Ovarian/fallopian tube/primary peritoneal cancer: initial workup; during primary chemotherapy; monitoring/follow-up for complete response as clinically indicated. Ovarian cancers (less common) and subtypes: monitoring/follow-up as specified with surveillance frequency guidance.
Lactate dehydrogenase (LDH) — Indications: B-cell lymphomas (multiple subtypes): workup. Bone neoplasms: workup. Chronic lymphocytic leukemia/small lymphocytic lymphoma: workup and at transformation or histologic progression (if applicable).
Serum tumor marker (generic) — Indications: Hairy cell leukemia: workup; Kidney cancer: initial workup; Melanoma (cutaneous and uveal): workup for metastatic or recurrent disease; Multiple myeloma: initial workup; surveillance as needed post primary treatment for solitary plasmacytoma or minimal marrow involvement; Ovarian/fallopian tube/primary peritoneal cancer: initial workup; during primary chemotherapy; monitoring/follow-up for complete response as clinically indicated; Primary cutaneous lymphomas: workup; Systemic light chain amyloidosis: initial diagnostic workup; Systemic mastocytosis: initial diagnostic workup; T-cell lymphomas (various): workup; staging (breast implant-associated ALCL only); Testicular cancer: nonseminoma and pure seminoma: post-diagnostic workup; risk classification; surveillance as specified; Waldenström macroglobulinemia/lymphoplasmacytic lymphoma: workup.
Serum free light chain — Indications: Multiple myeloma: initial diagnostic workup; surveillance (up to once per month). Systemic light chain amyloidosis: initial diagnostic workup.up to once per month
Troponin T — Indications: Systemic light chain amyloidosis: initial diagnostic workup.
Tryptase — Indications: Systemic mastocytosis: initial diagnosis.

Frequency / Surveillance Notes

Except where otherwise specified, quarterly measurement is permitted for follow-up/monitoring/surveillance.

ANY of the following

General rule: quarterly measurement of designated serum tumor markers is permitted for follow-up, monitoring, and/or surveillance unless specific more/less frequent intervals are provided for particular indications.quarterly measurement
See specific marker guidance for exceptions.
Specific surveillance intervals are listed with certain markers/indications (e.g., AFP every 3-6 months for 2 years then every 6 months; CA 19-9 and CEA schedules; germ cell tumor surveillance schedules; beta-hCG weekly during treatment for gestational trophoblastic neoplasia then monthly for 12 months; serum free light chain up to once per month).see marker-specific thresholds

Provider Actions / Billing Impact

Documentation Required

Indication documentation required

Document the specific covered indication on the medical record and claim to demonstrate the test is being ordered for a policy-listed purpose (for example: the cancer type, stage, and whether the test is for initial workup, monitoring, surveillance, or other listed purpose). Coverage is contingent on the indication matching one of the policy‑listed indications for the measured serum tumor marker.

Include cancer type and clinical purpose (workup, monitoring, surveillance, etc.)
Specify staging or timing when relevant (e.g., postoperative, during chemotherapy)
Indicate surveillance frequency if applicable (per policy-specified intervals)

Billing Rule

Use applicable CPT/HCPCS codes

Report laboratory tests using the applicable CPT/HCPCS procedure codes listed in the policy when submitting claims. Use the specific codes for the analyte or proprietary assay where available; if a proprietary or algorithmic multianalyte test has no specific code, report the applicable unlisted code as indicated.

81479
81599
82105
82107
82232
82308
82378
83520
83521
83615
83789
83880
83950
83951
84075
84078
84080
84484
84702
84703
84704
84999
86300
86301
86304
86305
86316
86336
0003U

Denial Risk

Claims for non-listed indications/test panels

Claims for use of biomarkers for cancer indications not specified in this policy, for serum tumor markers not addressed by the policy, or for proteomic pattern analysis for cancer screening are not covered and are at risk of denial. Ensure the requested test and indication are described in the policy prior to billing to avoid claim denial.

OpenPayer

Serum Tumor Markers for Malignancies (Commercial, BlueCare) – G2124

Coverage Summary

Medical-Necessity Criteria

Not Covered / Does Not Meet Coverage Criteria

Coding (CPT / HCPCS)

Provider Actions / Billing Impact

Background & Evidence

Revision History

81479	Unlisted molecular pathology procedure.
81599	Unlisted multianalyte assay with algorithmic analysis.
82105	Alpha-fetoprotein (AFP); serum.
82107	Alpha-fetoprotein (AFP); AFP-L3 fraction isoform and total AFP (including ratio).
82232	Beta-2 microglobulin.
82308	Calcitonin.
82378	Carcinoembryonic antigen (CEA).
83520	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified.
83521	Immunoglobulin light chains (i.e., kappa, lambda), free, each.
83615	Lactate dehydrogenase (LD), (LDH).